In the field of renin-angiotensin system (RAS) research, the functional regulation of angiotensin-converting enzyme 2 (ACE2) has always been one of the core directions. As a key target for regulating blood pressure and cardiovascular function, specific inhibitory tools for ACE2 are crucial for mechanism research. What we are going to share today is DX-600, a polypeptide-specific inhibitor of ACE2 with the CAS number 478188-26-0.
The most prominent advantage of DX-600 lies in its extremely high targeting specificity. Studies have confirmed that it can act precisely on ACE2 without cross-reacting with angiotensin-converting enzyme (ACE) of the same family. This characteristic provides a key guarantee for researchers to avoid interference and accurately analyze the independent functions of ACE2. Structurally, DX-600 is a polypeptide containing 26 amino acid residues. The N-terminal acetylation modification enhances its stability, while the disulfide bond formed between Cys6 and Cys17 stabilizes its three-dimensional conformation, ensuring its efficient binding to the active site of ACE2. Its inhibition constant Ki can reach 2.8 nM, exhibiting potent inhibitory activity.
In in vitro experiments, DX-600 has demonstrated reliable research value. Researchers verified in three human-derived cell lines (Calu-3, Caco-2, and Huh-7) that the ACE2 enzyme activity in cell lysates, culture supernatants, and living cells of Calu-3 cells, which have the highest ACE2 expression level, can be effectively inhibited by DX-600, and obvious effects can be observed after incubation at a concentration of 10 μM for 1 hour. It is worth noting that in vivo experiments have shown that DX-600 has species specificity, which can only block the activity of human-derived ACE2 but has no inhibitory effect on the reactions driven by mouse ACE2. This finding provides an important reference for model selection in preclinical research.
With these characteristics, DX-600 has become an important research tool in the fields of cardiovascular diseases, metabolic diseases, etc. For example, in the research on diabetes-related cardiovascular dysfunction, DX-600 has been used to verify the impact of ACE2 activity regulation on disease progression, providing direct evidence for analyzing the pathological mechanism of RAS system imbalance. Relevant research results have been cited in many literatures, including the 2023 study on the antiviral stability of ACE2-Fc fusion protein published in Communications Biology.
For researchers focusing on ACE2 function research, a tool molecule with high specificity and stable activity can greatly improve research efficiency. The unique advantages of DX-600 endow it with irreplaceable value in the research on RAS system regulation mechanisms and the pathology of related diseases, providing strong support for scientific research breakthroughs in relevant fields.
